MetaStat Insight has published a comprehensive market study projecting the Global Helicobacter Pylori Test Market to expand from USD 479.3 million in 2025 to USD 769.7 million by 2033, registering a compound annual growth rate (CAGR) of 6.1% over the forecast period. Helicobacter pylori (H. pylori) is a digestive bacterial infection capable of causing peptic ulcers, chronic gastritis, and stomach cancer. Diagnostic testing for H. pylori utilizes endoscopic and non-endoscopic procedures to identify bacterial presence in the stomach and upper small intestine.
The diagnostic industry is primarily driven by the widespread global disease burden, as H. pylori currently affects roughly 50% of the world's population. In the United States, infection rates sit between 30% and 40%, showing distinct age and ethnic disparities. Estimated prevalence stands at 20% for Americans under 30 years old and increases to 50% for individuals over 60. Demographically, prevalence reaches 60% in Hispanics and over 54% in African Americans, compared to 20% in white populations. Environmental factors such as inadequate sanitation, poor personal hygiene, contaminated food or water, and high population density continue to accelerate market demand. Conversely, market growth in underdeveloped countries is hindered by a lack of public awareness regarding transmission routes, carcinogenic impacts, and prevention methods. However, rising adoption of point-of-care testing devices offers significant future market opportunities.
Categorized by technology, the market includes Point-of-Care (POC), Immunoassays, and Molecular Diagnostics. Point-of-Care held the dominant market position in 2019, driven by sustained R&D investments and commercial launches. A prime example includes Exalenz Bioscience’s BreathID Hp Lab system, an intuitive solution designed for automated batch testing to detect active H. pylori infections. Beyond technology, the market is segmented by Type into Endoscopic and Non-Endoscopic, and by End User into Hospital & Clinics, Diagnostic Center, and Others.
Geographically, the industry spans North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Europe demonstrated strong growth in 2019 due to new technology commercialization, corporate partnerships, and public awareness initiatives. Programs led by organizations like the Healthy Stomach Initiative (HSI) have promoted research into gastroenteritis, functional dyspepsia, and gastric cancer. With H. pylori linked to at least 90% of gastric cancer cases, government and clinical data emphasize early testing as a key driver for cancer prevention and extended patient survival. In North America, regulatory approvals continue to propel market activity. For example, TECHLAB, Inc. earned U.S. FDA clearance on August 21, 2018, for its non-invasive diagnostic products, including the 30-minute rapid H. PYLORI QUIK CHEK and the high-volume 96-well plate H. PYLORI CHEK test.
Key companies operating within the global landscape include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Cardinal Health, Bio-Rad Laboratories, Inc., QIAGEN, Quest Diagnostics Incorporated, Meridian Bioscience, CorisBioconcept SPRL, and Biohit Oyj. Industry leaders consistently adopt strategies such as clinical research studies, public awareness programs, commercialization efforts, and joint ventures to enhance market competitiveness.
About MetaStat Insight
MetaStat Insight is an industry research and consulting firm supplying detailed sector insights, market share analysis, and long-term forecasts across global markets